Natixis’s KalVista Pharmaceuticals KALV Stock Holding History

Natixis’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,000	Closed	-$48.1K	–	1105
2023 Q3	$48.1K	Buy	+5,000	New	+$51.1K	﹤0.01%	828

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Natixis's KALV Position: Q4 2023 in Review

Natixis sold out of KalVista Pharmaceuticals (KALV) in Q4 2023, closing a stake of 5,000 shares — an estimated $48.1K sold.

Natixis first reported a position in KALV in Q3 2023 and held it in 1 quarter. The position peaked at $48.1K in Q3 2023. 93 funds tracked by Wall St. Rank hold KALV as of Q4 2023.

Natixis reported no remaining KalVista Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Natixis sold 5,000 KalVista Pharmaceuticals shares in Q4 2023, an estimated $48.1K.
Natixis first reported a position in KalVista Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Natixis's KalVista Pharmaceuticals position peaked at $48.1K in Q3 2023.
93 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2023.

Based on Natixis's 13F filing for Q4 2023, filed 13 Feb 2024.